Press room » Aston Health news » Initial results of the Program for Assessing Diagnosis and Treatment of HL in the N-W District

Initial results of Multicenter Cooperative Prospective-Retrospective Observational Program to Assess Diagnosis and Treatment of Hodgkin's Lymphoma in the North-Western District of Russia

Publication date: 1 february 2018

Aston Health in collaboration with the leading onco-hematologists from Research Institute of Oncology and Research Institute of Pediatric Oncology, Hematology and Transfusiology has been conducting an observational program to evaluate current practices in diagnosis and treatment of Hodgkin's Lymphoma (LH) in the North-Western Russia.

The purpose of the research is to obtain the real-world evidence on routine clinical practice for Hodgkin's Lymphoma and compare it with the suggested prospective treatment regimen. 

The scientific and administrative support for the project is provided by Advisory Board, which includes the prominent Russian experts in hematology.

The Program was approved by the Ethics Committee of the First St. Petersburg State Medical University and Research Institute of Oncology. The two were designated as reference centers to provide in-person and online consultations to practitioners from the regional clinics and the patients referred from these clinics. Altogether, the clinical outcomes of 900 patients will be reviewed during a 7-year study period.

As of January 31, 2018, ten regional medical centers were engaged in research, and over 100 patients were registered in the online database of the Program.

Aston Health runs the project using proprietary QUINTA® platform designed to collect, manage and store large amount of data. The patients’ personal data and sensitive health information is handled in compliance with Russian Data Protection Regulation.

Aston Health invites clinicians (onco-hematologists) to join the Program. If you are interested in joining the Program, please contact Dmitry Kosov, Head of Clinical registry department: d.kosov@aston-health.com 

Under the Program, an option of differential immunohistochemical diagnosis of LH is available. To learn more about this, please call the hotline number: 8-800-100-13-74 (6:00am to 6:00pm). 

CJSC Aston Consulting, 1999-2017